Cite
HARVARD Citation
Mease, P. et al. (n.d.). 165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: pooled results from three phase III randomised controlled trials. Rheumatology. p. . [Online].